Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Biotest (FSE:BIO) will acquire NABI's Nabi Biologics group for $185 million in cash. BIO said the group complements its European plasma protein business and gives it
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury